Skip to main content

Lenvatinib Side Effects

Medically reviewed by Last updated on Feb 13, 2024.

Applies to lenvatinib: capsule oral, oral capsule.

Serious side effects of Lenvatinib

Along with its needed effects, lenvatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lenvatinib:

More common

Less common

Incidence not known

Other side effects of Lenvatinib

Some side effects of lenvatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lenvatinib: oral capsule.


Very common (10% or more): Hypertension (73%)

Common (1% to 10%): Hypotension, QT prolongation, arterial thromboembolic event, cardiac dysfunction (cardiac failure, decreased ventricular function, pulmonary edema), myocardial infarction, cerebrovascular accident[Ref]


Very common (10% or more): Proteinuria (34%), renal impairment (14%)

Common (1% to 10%): Increased creatinine, renal failure

Postmarketing reports: Nephrotic syndrome[Ref]


Very common (10% or more): Hemorrhagic events (35%)

Common (1% to 10%): Decreased platelet count

Postmarketing reports: Arterial (including aortic) aneurysms, dissections, and rupture, impaired wound healing[Ref]


Common (1% to 10%): Hyperbilirubinemia, increased alkaline phosphatase, increased ALT, increased AST

Very rare (less than 0.01%): Hepatic failure, acute hepatitis

Postmarketing reports: Cholecystitis[Ref]


Very common (10% or more): Diarrhea (67%), nausea (47%), stomatitis (41%), vomiting (36%), abdominal pain (31%), constipation (29%), oral pain (25%), dry mouth (17%), dyspepsia (13%)

Common (1% to 10%): GI perforation/fistula, increased serum amylase, increased lipase

Postmarketing reports: Pancreatitis, increased amylase[Ref]

Nervous system

Very common (10% or more): Headache (38%), dysgeusia (18%), dizziness (15%)

Common (1% to 10%): Reversible posterior leukoencephalopathy syndrome[Ref]


Very common (10% or more): TSH suppression impairment (up to 88%)[Ref]


Very common (10% or more): Decreased appetite (54%), weight decreased (51%)

Common (1% to 10%): Dehydration, hypoalbuminemia, hypomagnesemia, hypoglycemia, hypocalcemia, hypercalcemia, hyperkalemia, hypercholesterolemia[Ref]


Very common (10% or more): Palmar-plantar erythrodysesthesia (32%), rash (21%), alopecia (12%)

Common (1% to 10%): Hyperkeratosis[Ref]


Very common (10% or more): Urinary tract infections (11%)[Ref]


Very common (10% or more): Dental and oral infections (10%)[Ref]


Very common (10% or more): Arthralgia/myalgia (62%)

Uncommon (0.1% to 1%): Osteonecrosis of the jaw[Ref]


Very common (10% or more): Fatigue (67%), peripheral edema (21%)[Ref]


Very common (10% or more): Insomnia (12%)[Ref]


Very common (10% or more): Dysphonia (31%), cough (24%), epistaxis (12%)

Common (1% to 10%): Pulmonary embolism[Ref]

Frequently asked questions


1. (2015) "Product Information. Lenvima (lenvatinib)." Eisai Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.